Masimo Corp

Latest Results (15.11.2025):

Masimo Corp’s second quarter 2025 financial results demonstrate solid performance with strong growth in both GAAP and non‐GAAP measures. The company reported GAAP revenue of $371 million (8% growth) and non‐GAAP revenue of $370 million (7% growth on a constant currency basis), with non‐GAAP earnings per diluted share soaring 46% to $1.33. Overall, these results underscore sustained momentum in Masimo Corp’s core healthcare business, complemented by effective tariff mitigation and a confident outlook for continued growth.

GAAP Revenue Growth

Masimo Corp reported GAAP revenue of $371 million for Q2 2025, marking an 8% increase, which signals expanding market penetration and robust demand in its core health care business.

Non‐GAAP Performance

The non‐GAAP revenue reached $370 million, growing at 7% on a constant currency basis, while non‐GAAP net income per diluted share stood at $1.33, reflecting a 46% year-over-year increase. These figures highlight the company’s strong operational performance by adjusting for various one-time costs and fluctuations.

Earnings and Tariff Mitigation

GAAP net income per diluted share came in at $0.82. Meanwhile, effective tariff mitigation measures reduced the estimated impact by 50%, demonstrating Masimo’s proactive financial management and strategic planning in navigating international trade challenges.

Forward Guidance and Outlook

Looking ahead for continuing operations in 2025, the company updated its guidance with non‐GAAP revenue expected to be between $1,505 and $1,535 million, along with operating profit and margin targets adjusted for both scenarios with and without tariff impacts. This outlook reinforces confidence in ongoing revenue expansion and margin improvement amid external challenges.